Question follow-through · 54852
Rare Diseases: Drugs
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of suspending the medicines repurposing programme on people affected by rare conditions.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 30 May 2025
- Target answer date
- 3 Jun 2025
- Answer
- 6 Jun 2025 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Cannabis: Medical Treatments · 18 Nov 2025
- Cannabis: Medical Treatments · 18 Nov 2025
- Multiple Sclerosis: Health Services · 9 Dec 2025
- Liver Diseases: Health Services · 10 Jul 2026
- Liver Diseases: Health Services · 10 Jul 2026
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
30 May 2025
Question tabled
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of suspending the medicines repurposing programme on people affected by rare conditions.
3 Jun 2025
Target answer date
Date supplied by the official written-questions record.
6 Jun 2025
Answer published
In April 2025, a decision was made to suspend the national Medicines Repurposing Programme. The decision was made with consideration to the following factors: The programme team and partners have learned that there are fewer repurposing opportunities in p...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Cannabis: Medical Treatments
18 Nov 2025 · To ask the Secretary of State for Health and Social Care, whether he plans to bring responsibility for medical cannabis policy and governance to his Department in line with Schedule 2 medicines.
Cannabis: Medical Treatments
18 Nov 2025 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support and fund clinical trials aimed at achieving licensing and NHS access for complex, cannabis-based medicines used in the treatment of severe, drug-resis
Multiple Sclerosis: Health Services
9 Dec 2025 · To ask the Secretary of State for Health and Social Care, what data his department collects to monitor potential inequalities in multiple sclerosis care access; and how those findings are used to inform policy and service delivery improvements.
Liver Diseases: Health Services
10 Jul 2026 · To ask the Secretary of State for Health and Social Care, what funding has been allocated to the NHS Liver Transformation Programme for 2026-27.
Liver Diseases: Health Services
10 Jul 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the NHS Liver Transformation Programme is adequately staffed and prioritised during the ongoing reorganisation of NHS England.
Liver Diseases: Health Services
10 Jul 2026 · To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the NHS Liver Transformation Programme reduces health inequalities in liver disease outcomes for people living in areas with high levels of deprivation.
Drugs: Rare Diseases
28 Aug 2026 · To ask the Secretary of State for Health and Social Care, how treatments for rare conditions will be prioritised for inclusion in the Government’s proposed pilot on supporting faster access to innovative medicines, as part of the UK-US pharmaceutical agre
Drugs: Rare Diseases
28 Aug 2026 · To ask the Secretary of State for Health and Social Care, further to the UK-US pharmaceutical agreement, how the Government’s proposed pilot on productivity benefits in medicines assessment will account for the wider value of treatments for rare condition
Drugs: Rare Diseases
28 Aug 2026 · To ask the Secretary of State for Health and Social Care, how patient organisations representing people living with rare conditions will be consulted on the development of new pilots being delivered as part of the UK-US trade agreement.
Liver Diseases: Health Services
7 Sept 2026 · To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce geographic variation in liver disease (a) diagnosis (b) treatment and (c) health outcomes.
Liver Diseases: Health Services
7 Sept 2026 · To ask the Secretary of State for Health and Social Care, what steps her Department is taking to reduce health inequalities in liver disease outcomes in the North West.